IMAGENEBIO INC (IMA) Stock Price, Forecast & Analysis
USA - NASDAQ:IMA - US45175G2075 - Common Stock
IMA Key Statistics, Chart & Performance
The current stock price of IMA is 8.29 USD. In the past month the price increased by 4.15%.
IMA Latest News, Press Relases and Analysis
IMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.77B |
Related stock screener links
About IMA
Company Profile
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Company Info
IMAGENEBIO INC
12526 High Bluff Drive
San Diego CALIFORNIA US
Employees: 9
Phone: 18573438292
IMAGENEBIO INC / IMA FAQ
Can you describe the business of IMAGENEBIO INC?
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
What is the stock price of IMAGENEBIO INC today?
The current stock price of IMA is 8.29 USD. The price decreased by -1.19% in the last trading session.
Does IMAGENEBIO INC pay dividends?
IMA does not pay a dividend.
What is the ChartMill rating of IMAGENEBIO INC stock?
IMA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists IMA stock?
IMA stock is listed on the Nasdaq exchange.
How is the market expecting IMA stock to perform?
6 analysts have analysed IMA and the average price target is 281.52 USD. This implies a price increase of 3295.9% is expected in the next year compared to the current price of 8.29.
IMA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IMA.
IMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMA. IMA has a great financial health rating, but its profitability evaluates not so good.
IMA Financial Highlights
Over the last trailing twelve months IMA reported a non-GAAP Earnings per Share(EPS) of -7.68. The EPS decreased by -68.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.79% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |
IMA Forecast & Estimates
6 analysts have analysed IMA and the average price target is 281.52 USD. This implies a price increase of 3295.9% is expected in the next year compared to the current price of 8.29.